Pharmaceutical company Galderma has released data from a clinical trial evaluating the effectiveness of injectable treatments for facial volume loss.
Galderma investigated the aesthetic outcomes and appearance of Restylane Lyft or Volyme in combination with Sculptra for cheek or jawline augmentation, and correction of contour deficiencies in patients experiencing facial volume loss associated with medication-driven weight loss.
The nine-month phase IV clinical trial consisted of 41 participants, 39 female, aged 32 to 79 – with 35 completing the full trial. The trial used the SHAPE Up Holistic Individualised Treatment (HIT) and improvements were measured using bioinstrumentation tools, including a corneometer. According to Galderma, Restylane was found to improve skin hydration by a peak of 41.52% at month five, with a significant improvement of 32.9% maintained at month nine. Sculptra was observed improving skin radiance by a peak of 16.65% at month seven, sustaining a significant 15.85% improvement at month nine.
Clinical trial investigator and plastic surgeon Mr Paul Lorenc said, “The improvements we observed with Sculptra and Restylane at nine months are hugely encouraging and represent a meaningful step forward in addressing the most predominant aesthetic concerns of patients along their weight loss journey.”
Galderma is exhibiting as Headline Sponsor at CCR this month.